title: Interactions between dietary oil treatments and genetic variants modulate fatty acid ethanolamides in plasma and body weight composition.
abstract: Fatty acid ethanolamides (FAE), a group of lipid mediators derived from long-chain fatty acids (FA), mediate biological activities including activation of cannabinoid receptors, stimulation of fat oxidation and regulation of satiety. However, how circulating FAE levels are influenced by FA intake in humans remains unclear. The objective of the present study was to investigate the response of six major circulating FAE to various dietary oil treatments in a five-period, cross-over, randomised, double-blind, clinical study in volunteers with abdominal obesity. The treatment oils (60 g/12 552 kJ per d (60 g/3000 kcal per d)) provided for 30 d were as follows: conventional canola oil, high oleic canola oil, high oleic canola oil enriched with DHA, flax/safflower oil blend and corn/safflower oil blend. Two SNP associated with FAE degradation and synthesis were studied. Post-treatment results showed overall that plasma FAE levels were modulated by dietary FA and were positively correlated with corresponding plasma FA levels; minor allele (A) carriers of SNP rs324420 in gene fatty acid amide hydrolase produced higher circulating oleoylethanolamide (OEA) (P=0·0209) and docosahexaenoylethanolamide (DHEA) levels (P=0·0002). In addition, elevated plasma DHEA levels in response to DHA intake tended to be associated with lower plasma OEA levels and an increased gynoid fat mass. In summary, data suggest that the metabolic and physiological responses to dietary FA may be influenced via circulating FAE. Genetic analysis of rs324420 might help identify a sub-population that appears to benefit from increased consumption of DHA and oleic acid.
authors.affiliation: 1Department of Human Nutritional Sciences,University of Manitoba,Winnipeg,MB R3T 2N2,Canada.
authors.forename: Shuaihua
authors.initials: S
authors.lastname: Pu
authors.affiliation: 1Department of Human Nutritional Sciences,University of Manitoba,Winnipeg,MB R3T 2N2,Canada.
authors.forename: Peter
authors.initials: P
authors.lastname: Eck
authors.affiliation: 3Department of Nutritional Sciences, Faculty of Medicine,University of Toronto,Toronto,ON M5S 3E2,Canada.
authors.forename: David J A
authors.initials: DJ
authors.lastname: Jenkins
authors.affiliation: 5Keenan Research Centre for Biomedical Science,St. Michael's Hospital,Toronto,ON M5B 1W8,Canada.
authors.forename: Philip W
authors.initials: PW
authors.lastname: Connelly
authors.affiliation: 7Institute of Nutrition and Functional Foods,Université Laval,Québec,QC G1V 0A6,Canada.
authors.forename: Benoît
authors.initials: B
authors.lastname: Lamarche
authors.affiliation: 8Department of Nutritional Sciences,Pennsylvania State University,University Park,PA 16802,USA.
authors.forename: Penny M
authors.initials: PM
authors.lastname: Kris-Etherton
authors.affiliation: 8Department of Nutritional Sciences,Pennsylvania State University,University Park,PA 16802,USA.
authors.forename: Sheila G
authors.initials: SG
authors.lastname: West
authors.affiliation: 8Department of Nutritional Sciences,Pennsylvania State University,University Park,PA 16802,USA.
authors.forename: Xiaoran
authors.initials: X
authors.lastname: Liu
authors.affiliation: 1Department of Human Nutritional Sciences,University of Manitoba,Winnipeg,MB R3T 2N2,Canada.
authors.forename: Peter J H
authors.initials: PJ
authors.lastname: Jones
mesh_terms: D050154:Adiposity; D000328:Adult; D000483:Alleles; D000581:Amidohydrolases / Q000235:genetics* / Q000378:metabolism; D015992:Body Mass Index; D018592:Cross-Over Studies; D004038:Diet, Reducing / Q000379:methods; D004042:Dietary Fats, Unsaturated / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004281:Docosahexaenoic Acids / Q000097:blood* / Q000378:metabolism; D004311:Double-Blind Method; D063388:Endocannabinoids / Q000097:blood* / Q000378:metabolism; D004983:Ethanolamines / Q000097:blood* / Q000378:metabolism; D005260:Female; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D054647:Nutrigenomics / Q000379:methods; D056128:Obesity, Abdominal / Q000097:blood / Q000178:diet therapy* / Q000235:genetics / Q000378:metabolism; D009829:Oleic Acids / Q000097:blood* / Q000378:metabolism; D010739:Phospholipase D / Q000235:genetics / Q000378:metabolism; D000099252:Fatty Acid Amide Hydrolases
chemical_list: D000581:Amidohydrolases; D004042:Dietary Fats, Unsaturated; D004281:Docosahexaenoic Acids; D063388:Endocannabinoids; D004983:Ethanolamines; D009829:Oleic Acids; D010739:Phospholipase D; D000099252:Fatty Acid Amide Hydrolases; C561061:N-docosahexaenoylethanolamide; C488250:oleoylethanolamide; C581518:NAPEPLD protein, human
keywords: AA arachidonic acid; AEA 
                    N-arachidonoylethanolamine; ALA 
                    α-linolenic acid; ALEA 
                    α-linolenoylethanolamide; Body weight; Canola conventional canola oil; CanolaDHA DHA-enriched canola oil; CanolaOleic high oleic canola oil; CornSaff a blend of corn oil and safflower oil; DHEA docosahexaenoylethanolamide; Dietary oil treatments; FA fatty acid; FAAH fatty acid amide hydrolase; FAE fatty acid ethanolamide; Fatty acid ethanolamides; FlaxSaff a blend of flax oil and safflower oil; Genetic variants; Intervention trial; LA linoleic acid; LEA linoleoylethanolamide; NAPE-PLD 
                    N-acylphosphatidylethanolamine-hydrolysing phospholipase D; OA oleic acid; OEA oleoylethanolamide; PEA palmitoylethanolamide